Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product

Cerebral Adrenoleukodystrophy (CALD) Clinical Trial

Official title:
Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product

Status Active, not recruiting

Clinical Trial Summary

This is a multi-center, long-term safety and efficacy follow-up study for participants with cerebral adrenoleukodystrophy (CALD) who have received Lenti-D Drug Product (eli-cel) in a parent clinical study. After completing a parent clinical study (approximately 2 years), eligible participants will be followed for an additional 13 years for a total of 15 years post-drug product infusion. No investigational drug product will be administered in this study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adrenoleukodystrophy
Adrenoleukodystrophy (ALD)
Cerebral Adrenoleukodystrophy (CALD)
X-Linked Adrenoleukodystrophy (X-ALD)

Clinical Trial Details

NCT number	NCT02698579
Study type	Observational
Source	bluebird bio
Contact
Status	Active, not recruiting
Phase
Start date	January 22, 2016
Completion date	August 2038

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06224413` - A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel
Recruiting	`NCT05819866` - A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy	Phase 3
Completed	`NCT03852498` - A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)	Phase 3
Completed	`NCT01896102` - A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)	Phase 2/Phase 3
Terminated	`NCT02204904` - Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)